Indeed, this was of particular advantage in targeting heterogeneous tumors composed of MHC-class I+ and MHC-class I− tumor cells, where HER2TCR+NKp30+CD8+ T cells showed the capacity to eliminate tumor cells even in the absence of MHC-class I and antigen display. The gene discussed is CD8A; the disease is neoplasm.